argenx SE announced new clinical data presentations for VYVGART and pipeline candidates at the 2026 AAN Annual Meeting, including positive Phase 3 ADAPT OCULUS results in ocular MG, ADAPT SERON data in AChR-Ab negative gMG subtypes, and CIDP analyses, supporting label expansions and earlier treatment use.
Key takeaways
Phase 3 ADAPT OCULUS study shows VYVGART’s potential as first targeted treatment for ocular MG
Phase 3 ADAPT SERON data demonstrate VYVGART efficacy in gMG patients without detectable AChR-Ab across MuSK+, LRP4+, and triple seronegative subtypes
ADHERE post-hoc analysis supports VYVGART Hytrulo use in treatment-naïve CIDP patients
Phase 1b ARGX-119 trial shows favorable safety and functional improvements in DOK7 CMS
Presentations at 2026 AAN Annual Meeting April 18-22 in Chicago include oral sessions on ADAPT SERON and ARGX-119